Figure 3.
[18F] AV-1451 tau-PET shows minimal uptake in a normal control patient (top row), mild-moderate uptake in the dentate nucleus of the cerebellum, midbrain and basal ganglia in a patient with progressive supranuclear palsy (PSP), a primary 4R tauopathy (2nd row), and striking uptake in the cortex in a patient with typical Alzheimer’s disease (AD), a 3R + 4R tauopathy, for comparison (bottom row).